Are Topical Steroids Enough to Treat Nasal Polyps?
Nasal polyps are noncancerous, inflamed growths in the lining of the nasal passages and sinuses that can cause congestion, loss of smell, facial pressure, and recurrent infections. Patients and clinicians frequently ask whether topical steroids alone — typically intranasal corticosteroid sprays or irrigations — are enough to treat polyps, or whether oral steroids, biologic drugs, or surgery are needed. This article summarizes current, evidence-based options for medical management, explains how topical corticosteroids fit into care pathways, and outlines when escalation to systemic therapy or biologics may be considered. This content is informational and does not replace personalized medical advice; consult an ENT specialist, allergist, or your primary care clinician for decisions about diagnosis and treatment.
How nasal polyps develop and why treatment matters
Nasal polyps most commonly occur in people with chronic rhinosinusitis with nasal polyps (CRSwNP), a long-term inflammatory condition often driven by type 2 inflammation characterized by eosinophils and cytokines such as IL-4, IL-5 and IL-13. Polyps form when chronic inflammation causes the mucosal lining to swell and protrude into nasal passages. Left uncontrolled, polyps can worsen nasal obstruction, increase the risk of sinus infections, and significantly reduce quality of life, including smell and sleep. Understanding the underlying inflammatory pattern (endotype) helps guide treatment choices, since some therapies target generalized inflammation while newer biologic drugs target specific immune pathways implicated in polyposis.
Key components of medical therapy for nasal polyps
Medical management typically begins with intranasal corticosteroids (INCS) delivered by spray, drops, or irrigations; saline rinses; and addressing comorbidities such as allergic rhinitis and asthma. Short courses of oral corticosteroids can rapidly reduce polyp size and symptoms but carry systemic risks with repeated use. For patients with severe or recurrent disease, biologic monoclonal antibodies that target type 2 inflammation (for example, dupilumab, omalizumab, mepolizumab) are now part of treatment algorithms when standard medical and surgical options are inadequate or contraindicated. Functional endoscopic sinus surgery (FESS) is considered when symptoms persist despite optimized medical therapy and significant anatomic obstruction or chronic infection exists.
Are topical steroids enough? Benefits and limitations
Intranasal corticosteroids are the mainstay first-line therapy for most patients with nasal polyps. High-quality systematic reviews and guideline panels report that INCS reduce polyp size modestly, improve nasal congestion, and improve disease-specific quality of life for many patients. They are safe for long-term use when used at recommended dosing and are generally well tolerated; local side effects include nasal dryness and occasional nosebleeds. However, for patients with large polyps, severe symptoms, loss of smell, or type 2 inflammatory endotypes, topical steroids alone often provide partial benefit and may not fully control disease or prevent recurrence. In these cases clinicians consider short systemic steroid bursts, biologic agents, or surgery as next steps.
Advanced options: systemic steroids, biologics, and when they are used
Short courses of oral corticosteroids are effective at quickly reducing polyp size and improving symptoms, but repeated systemic steroid use increases risk of adverse effects (weight gain, elevated blood sugar, bone loss, adrenal suppression) and guidelines recommend limiting repeated courses. For patients with severe CRSwNP that remains uncontrolled despite intranasal steroids and appropriate surgical management, biologic therapies that modulate type 2 inflammation have shown clinically meaningful improvements in polyp size, nasal obstruction, smell, and quality of life. Dupilumab — an antibody that blocks IL-4 and IL-13 signaling — has regulatory approval for adults with inadequately controlled CRSwNP and has demonstrated reductions in polyp size and surgery need in randomized trials. Omalizumab (anti-IgE) and mepolizumab (anti-IL-5) have also shown benefit in selected populations, particularly when asthma or allergic comorbidity is present. Biologics are typically considered for severe, recurrent disease after verifying appropriate criteria and discussing risks, monitoring, and costs with the treating physician.
Trends and innovations affecting local treatment choices
Recent years have seen two important trends: better patient endotyping to match treatments to underlying inflammation, and the integration of biologics into rhinology practice for refractory cases. Surgical techniques and perioperative topical steroid strategies have improved long-term outcomes and can make topical drugs more effective by restoring sinus ventilation and improving drug delivery. Drug-eluting sinus implants that release corticosteroid locally after surgery offer targeted, short-term anti-inflammatory action for certain postoperative situations. Guideline panels emphasize shared decision-making: for many patients, long-term intranasal steroids combined with saline rinses and optimized delivery methods remain the cornerstone, while biologics and systemic steroids are reserved for those with severe, refractory, or comorbid disease.
Practical tips for patients and clinicians
If you or a patient are managing nasal polyps, practical steps improve outcomes. First, confirm the diagnosis with nasal endoscopy or imaging and identify comorbidities such as asthma or aspirin sensitivity. Use intranasal corticosteroids daily and learn an effective delivery technique (e.g., head position, timing with saline irrigations) — in some cases steroid irrigations or drops prescribed by an ENT provide better contact with polyps than sprays. Reserve short oral steroid courses for acute exacerbations or severe symptoms and limit the number of courses per year. If symptoms persist or recur despite good adherence and optimal delivery, discuss referral for ENT evaluation, consideration of surgery to improve access for topical therapy, and assessment for biologic therapy eligibility. Always weigh benefits against risks, and discuss monitoring plans for systemic therapies.
Summary of current clinical wisdom
Topical intranasal corticosteroids are essential and effective first-line therapy for most patients with nasal polyps, offering symptom relief, reduced polyp size, and a favorable safety profile for long-term use. They are not always sufficient for severe or recurrent disease, where short courses of systemic steroids, surgical intervention, or biologic therapies may be indicated after specialist consultation. Advances in precision medicine, improved topical delivery, and approved biologic agents have expanded options but also added complexity; treatment choice should be individualized, guided by symptom severity, endotype, comorbidities, prior surgery, and patient preferences. Speak with an ENT specialist or allergist for tailored recommendations; this article does not replace clinical evaluation.
| Drug class / option | Examples | Role | Pros and cons |
|---|---|---|---|
| Intranasal corticosteroids (topical) | Fluticasone, mometasone, budesonide (sprays/irrigations) | First-line maintenance therapy | Safe long-term; modest-to-moderate symptom and size reduction; local side effects like epistaxis |
| Short-course oral corticosteroids | Prednisone/prednisolone (prescribed short-term) | Rapid symptom and polyp size reduction for exacerbations | Effective short-term; systemic risks with repeated use; limit frequency |
| Biologic therapies | Dupilumab, omalizumab, mepolizumab | For severe, refractory CRSwNP or when surgery unsuitable | Reduces polyp size and improves smell; costly; requires specialist monitoring |
| Surgery (FESS) | Endoscopic sinus surgery | Removes obstructing polyps, improves topical drug delivery | Can provide durable relief but polyps may recur; often combined with topical steroids post-op |
Frequently asked questions
- Q: Can nasal steroid sprays completely remove polyps?
A: Topical steroids often shrink polyps and improve symptoms but rarely eliminate large polyps completely. They are most effective when used consistently and with proper delivery technique; persistent or bulky polyps may require additional therapies.
- Q: When should I consider a biologic like dupilumab?
A: Biologics are considered for adults with severe CRSwNP that remains uncontrolled despite optimized topical therapy and, when appropriate, surgery. Eligibility typically includes objective measures of disease burden, prior treatments, and consideration of comorbid conditions such as asthma.
- Q: Are oral steroids safe for long-term use?
A: Repeated systemic steroid courses increase the risk of systemic complications and are generally limited; clinicians prefer to minimize cumulative steroid exposure and consider alternative long-term strategies for disease control.
- Q: Do saline rinses help?
A: Regular saline irrigation aids nasal hygiene, helps remove crust and secretions, and can improve delivery of topical steroids; it is commonly recommended alongside INCS.
Sources
- U.S. Food and Drug Administration – Dupixent (dupilumab) approval for CRSwNP (June 26, 2019)
- European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS 2020)
- Cochrane Review – Biologics for people with chronic rhinosinusitis
- StatPearls / NCBI – Nasal Polyps (overview of diagnosis and treatment considerations)
Medical disclaimer: This article summarizes general information and guideline-level evidence as of its publication and is not a substitute for professional medical evaluation. Treatment decisions should be individualized by qualified clinicians. If you have sudden severe symptoms (high fever, vision changes, severe facial pain, or rapidly worsening breathing), seek immediate medical attention.
This text was generated using a large language model, and select text has been reviewed and moderated for purposes such as readability.
